Clinical evaluation of the elecsys® CA 15-3 test in breast cancer patients

Clinical Laboratory

Volumn 49, Issue 1-2, 2003, Pages 15-24

  Stieber, Petra ^a   Molina, Rafael ^b   Chan, Daniel W ^c   Fritsche, Herbert A ^d   Beyrau, Ralf ^e   Bonfrer, Jean M G ^f   Filella, Xavier ^b   Gornet, Terrie G ^d   Hoff, Torsten ^g   Jäger, Wolfram ^h   Van Kamp, Gerard J ⁱ   Nagel, Dorothea ^a   Peisker, Klaus ^j   Sokoll, Lori J ^c   Troalen, Frédéric ^k   Untch, Michael ^a   Domke, Ingrid ^l  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HOSPITAL CLÍNIC   (Spain)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Institut fuer Klinische Chemie/Lab   (Germany)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^g Zentralkrankenhaus Links der Weser   (Germany)

^h Universitaetsfrauenklinik   (Germany)

ⁱ VU UNIVERSITY AMSTERDAM   (Netherlands)

^j St Elisabeth Krankenhaus   (Germany)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l Roche Diabetes Care GmbH   (Germany)

more..

Author keywords

Breast cancer; CA 15 3; Clinical evaluation; Diagnostic accuracy; Elecsys assay

Indexed keywords

CA 15-3 ANTIGEN;

ANALYTICAL EQUIPMENT; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; METASTASIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CA-15-3 ANTIGEN; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PREGNANCY; REFERENCE VALUES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 12244255056     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hilkens J, Kroezen V, Buijs F, et al. MAM-6, a carcinoma associated marker: preliminary characterization and detection in sera of breast cancer patients. In: Cerini RL, ed. Monoclonal antibodies and breast cancer. The Hague: Martinus Nijhoff, 1985: 28-42.
2. Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75: 1671-8.
3. Lamerz R. CA 15-3. In: Thomas L, ed. Clinical Laboratory Diagnostics. Frankfurt, Germany: TH-Books Verlag, 1998: 955-8.
4. Stieber P, Molina R, Chan DW et al. Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 immunoassay. Clin Chem 2001; 47: 2162-2164.
5. Hermanek P, Scheibe O, Spiessl B, Wagner G. Mammatumoren (ICD-O 174). In: Hermanek P, Scheibe O, Spiessl B, Wagner G, eds. TNM Klassifikation maligner Tumoren. Berlin, Heidelberg, New York, London, Paris, Tokyo: Springer-Verlag, 1987: 99-106
6. Erler K. Immunoassay systems using electrochemiluminescence detection. Wien Klin Wochenschr 1998; 110 (Suppl 3): 5-10
7. Weatherholt J, Loewen N, Leamons S, et al. Development of the CA 15-3 assay for the Abbott AxSYM. Clin Lab 1996, 42: 429-36.
8. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. J Clin Chem Clin Biochem 1983; 21: 709-20.
9. Hanley JA, McNeill BJ. The meaning and use of the area under a receiver operating characteristics curve. Radiology 1982; 143: 29-36
10. Hayes DF. Tumor markers for breast cancer. Hematol Oncol Clinics North Amer 1994; 8: 485-506
11. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. 1981; John Wiley 217-9.
12. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Research and Treatment 1989; 13: 123-33.
13. Colomer R, Ruibal A, Genolla J, Salvador L. Circulating CA 15-3 levels in non-malignant mammary malignancies; Br J Cancer 1989; 59: 283-6.
14. Langhammer HR, Elgas W, Laubenbacher Ch, et al. The role of CA 15-3 and CEA in the diagnosis of breast cancer tumor recurrence with special consideration given to the localization and extent of the metastases. Tumor Diagn Ther 1994; 15: 96-103.
15. Safi F, Kohler I, Röttinger E, Beger, HG. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. Cancer 1990; 68: 574-82.
16. Van Dalen A. Quality control and standardization of tumor marker tests. Tumor Biol 1993; 14: 131-5.
17. Hayward JL, Carbonne PPK, Heuson JC et al. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, Switzerland. Cancer 1979, 39: 1289-1294
18. Jaeger W. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Euro J Cancer Prevention 1993; 2 (Suppl 3): 133-9.
19. Markopoulos CJ, Gogas HJ, Alevizou-Terzaki BPh. et al. CA 15-3 in the prediction of recurrence of breast cancer. Breast Dis 1994; 7: 1-5.
20. Robertson J, Pearson D, Price MR, et al. Objective measurement of therapeutic response in breast cancer using tumor markers. J Clin Oncol 1992; 7: 1057-65.
21. Martoni A, Ercolino L, Bellanova B, et al. CA 15-3 and CEA plasma level monitoring in patients with breast cancer. Int J Biol Markers 1988; 3: 154-8.